Month: March 2026

Oxford: Owner of Tommy Bahama, Lilly Pulitzer and Johnny Was Reports Fourth Quarter and Full-Year Fiscal 2025 Results

Written by Customer Service on March 26, 2026. Posted in Earnings Releases And Operating Results.

Initiates fiscal 2026 guidance reflecting meaningfully improved profitability on modest sales growth driven by improvement at Tommy Bahama. Fiscal 2026 guidance includes revenues of $1.475 billion to $1.530 billion, GAAP EPS of $1.83 to $2.43 and adjusted EPS of $2.10 to $2.70; EPS expectations assume IEEPA tariff rates continued for balance of year. Increases quarterly dividend to $0.70 per share.ATLANTA, March 26, 2026 (GLOBE NEWSWIRE) — Oxford Industries, Inc. (NYSE:OXM) today announced financial results for its fourth quarter and full fiscal year 2025 ended January 31, 2026 and initiated guidance for the first quarter and full fiscal year 2026. Consolidated net sales in the fourth quarter of fiscal 2025 were $374 million compared to $391 million in the fourth quarter of fiscal 2024. Diluted loss per share on a GAAP basis...

Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

Written by Customer Service on March 26, 2026. Posted in Earnings Releases And Operating Results.

– Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Special Situations Funds, and Invus – – Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® – – Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 – – Initiated Phase 1 Study of RT-114 RaniPill® for the treatment of obesity in collaboration with ProGen – – Conference call today at 4:30 p.m. ET / 1:30 p.m. PT – SAN JOSE, Calif., March 26, 2026 (GLOBE NEWSWIRE) —...

CapsoVision Reports Fourth Quarter and Full Year 2025 Financial Results

Written by Customer Service on March 26, 2026. Posted in Earnings Releases And Operating Results.

SARATOGA, Calif., March 26, 2026 (GLOBE NEWSWIRE) — CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent HighlightsFourth quarter 2025 revenue was $3.9 million, a 13% increase over the fourth quarter of 2024. Full year 2025 revenue was $13.6 million, a 15% increase compared to full year 2024. New accounts grew 16% in the fourth quarter of 2025 over the comparable quarter in 2024. Full year 2025 new accounts grew 21% compared to full year 2024. CapsoCam Plus® used by over 161,000 patients as of December 31, 2025. Submitted 510(k) application to the Food and Drug Administration (FDA) for its in-house developed AI-assisted module for...

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Written by Customer Service on March 26, 2026. Posted in Earnings Releases And Operating Results.

Advancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026 Progressing enrollment for FDA-aligned Phase 3 trial in generalized myasthenia gravis (gMG) Positive progressive multiple sclerosis data underscore valuable pipeline-in-a-product opportunity with miv-cel Cash and cash equivalents of $279 million provide expected runway into 2028, funding SPS BLA filing, commercial launch, and Phase 3 gMG trial EMERYVILLE, Calif., March 26, 2026 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights and financial results for the fourth quarter and full year ended...

Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

Written by Customer Service on March 26, 2026. Posted in Earnings Releases And Operating Results.

Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women’s Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today reported financial results for the year ended December 31, 2025, and provided a business update. “We are not a company that is just getting into women’s health. We are a women’s health biotech company – and we believe 2026 is the year investors will get to see what ten years of that commitment actually looks like. We built the company to change how women experience healthcare. That change...

KOIL Energy Solutions Announces Dates for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

Written by Customer Service on March 26, 2026. Posted in Public Companies.

HOUSTON, March 26, 2026 (GLOBE NEWSWIRE) — Koil Energy Solutions, Inc. (OTCQB: KLNG), a specialist in deepwater energy production and distribution equipment and services, announced today that it will report its fourth quarter and full year 2025 results on Tuesday, March 31, 2026, before the market opens. KOIL will host an investor conference call to review its fourth quarter 2025 results on Tuesday, March 31, 2026, at 10:00am Eastern Time. Interested parties may listen to the call through a webcast link or using the dial in numbers. (See below details.) PARTICIPANT WEBCAST LINK: https://edge.media-server.com/mmc/p/qjebi4ez/ PARTICIPANT DIALS:PARTICIPANT DIAL IN (TOLL FREE) 1-833-630-1956PARTICIPANT INTERNATIONAL DIAL IN 1-412-317-1837 The earnings release and a replay of the conference call will also be available on the Company’s...

Loblaw February Food Inflation Report

Written by Customer Service on March 26, 2026. Posted in Public Companies.

TORONTO, March 26, 2026 (GLOBE NEWSWIRE) — Loblaw has issued its February Food Inflation Report, with context around what’s impacting food prices and what it expects in the future. At a high level, inflation cooled slightly in February. Overall CPI was 1.8%, down from 2.3% in January. The price of food purchased from stores also dropped, down 70 basis points from January at 4.1%. The price of food purchased from restaurants rose 7.8% in the month – a meaningful increase, especially considering prices also jumped a year ago when the GST/HST holiday concluded in February 2025. For more information, contact pr@loblaw.ca.

Kaldalón hf.: Results of the Annual General Meeting 2026

Written by Customer Service on March 26, 2026. Posted in Public Companies.

The following proposals were presented to the Annual General Meeting of Kaldalón hf., held at Reykjavík Natura, Nauthólsvegur 52, Reykjavík, on 26 March 2026 at 16:00. The Company’s 2025 Annual Financial Statements and decision on the allocation of profit or loss for the financial year The Company’s 2025 Annual Financial Statements were presented for confirmation and were unanimously approved. A proposal to pay a dividend to shareholders, i.e. the holders of shares not owned by Kaldalón, in the amount of ISK 1,000,000,000 for the 2025 operating year, corresponding to ISK 0.94 per share, was unanimously approved. Election and appointment of the Board of Directors and alternate directors The meeting had before it candidacies from five individuals for the Board of Directors and two individuals for the alternate board of Kaldalón hf. As no...

AS Pro Kapital Grupp announces identification and remediation of technical covenant breach under its outstanding bonds 2020/2028

Written by Customer Service on March 26, 2026. Posted in Public Companies.

AS Pro Kapital Grupp (the “Company”) hereby announces that on 25 March 2026, it identified that one of its subsidiaries, OÜ Kalaranna Kvartal, has been in breach of the maintenance test covenant on subsidiary level, pursuant to the terms and conditions (the “Terms and Conditions”) of the Company’s outstanding senior secured bonds 2020/2028 with ISIN SE0013801172, constituting a technical default under the Terms and Conditions (the “Covenant Breach”). The Covenant Breach has been continuing since 21.11.2025 and arose as a result of a loan incurred by OÜ Kalaranna Kvartal, the outstanding balance of which caused OÜ Kalaranna Kvartal to exceed the threshold allowed under the maintenance test covenant. Promptly following identification of the Covenant Breach, OÜ Kalaranna Kvartal has today partially repaid the relevant loan, thereby remedying...

SalMar – Key information relating to the cash dividend paid by SalMar ASA

Written by Customer Service on March 26, 2026. Posted in Public Companies.

Dividend amount: 10.0 per shareDeclared currency: NOK Last day including right: 23.06.2026Ex-date: 24.06.2026Record date: 25.06.2026Payment date: On or about 07.07.2026Date of approval: 23.06.2026 For more information, please contact:Håkon Husby, Head of IRTel: +47 936 30 449Email: hakon.husby@salmar.no This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Month: March 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals